CRDF — Cardiff Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1213037 ·
Last close
$1.54
Market Cap
$105.29M
52W High
$2.00
52W Low
$1.35
ADV30
1,399,177
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 41,000 | — | -12,850,000 | -12,345,000 | 49,172,000 | 8,544,000 | 14,463,000 |
| Dec 2025 | 243,000 | — | -7,827,000 | -7,216,000 | 61,884,000 | 17,470,000 | 16,496,000 |
| Sep 2025 | 120,000 | — | -11,974,000 | -11,258,000 | 63,780,000 | 10,135,000 | 14,990,000 |
| Jun 2025 | 121,000 | — | -14,777,000 | -13,943,000 | 75,739,000 | 10,784,000 | 17,133,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,417,000
Investing CF
$19,183,000
Financing CF
$2,683,000
CapEx
$-18,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.76
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-442,375,000
Inventory
—
Receivables
$191,000
ST Investments
$37,512,000
EBIT TTM
$-47,428,000
Pretax Income TTM
$-44,762,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$525,000
EBITDA
$-47,070,000
Free Cash Flow
$-20,021,500
Enterprise Value
$59,879,640
Total Cash
$46,056,000
Total Debt
$646,000
Shares Out
68,369,896
Trailing EPS
$-0.67
Book Value
$0.51
ROE
-84.8%
ROA
-44.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 593,000 | -48,960,000 | -45,851,000 | 61,884,000 | 16,496,000 | — | -37,923,000 |
| Dec 2024 | 683,000 | -48,651,000 | -45,431,000 | 97,190,000 | 14,241,000 | — | -37,693,000 |
| Dec 2023 | 488,000 | -45,412,000 | -41,441,000 | 81,637,000 | 11,898,000 | — | -30,887,000 |
| Dec 2022 | 386,000 | -39,902,000 | -38,704,000 | 116,191,000 | 9,848,000 | — | -33,820,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.81
Max Pain — expiry 2026-06-18
max pain strike: $1.50 · spot: $1.42 · call oi: 7,523 · put oi: 1,015
Expected Move to 2026-06-18:
±$0.17
(11.97%) —
implied range
$1.25 –
$1.59
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | $103.02M | $4.33 | — |
| CGTX | COGNITION THERAPEUTICS INC | $108.29M | $1.21 | — |
| ENGN | enGene Therapeutics Inc. | $108.52M | $1.62 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $100.28M | $1.75 | — |
| PTHS | Pelthos Therapeutics Inc. | $95.58M | $27.50 | — |
News headlines (Yahoo Finance, 1h cache)
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
2026-06-02 13:06 · Yahoo
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
2026-06-02 11:30 · Yahoo
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
2026-06-01 20:01 · Yahoo
CRDF: First Quarter 2026 Results
2026-05-22 14:15 · Yahoo
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
2026-05-21 21:00 · Yahoo
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
2026-05-20 18:05 · Yahoo
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
2026-05-14 20:10 · Yahoo
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28 20:01 · Yahoo
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
2026-04-27 11:00 · Yahoo
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
2026-04-21 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.